Update shared on07 Aug 2025
Fair value Decreased 8.48%The consensus analyst price target for QuidelOrtho has been revised downward, primarily reflecting a sharp deterioration in profitability—evidenced by a collapse in net profit margin and a spike in the future P/E ratio—with fair value lowered from $47.14 to $43.57.
What's in the News
- QuidelOrtho reiterated its full year 2025 earnings guidance, with expected revenues between $2.60 billion and $2.81 billion.
- Launched BUHLMANN fCAL turbo and fPELA turbo assays on VITROS Systems, enhancing non-invasive diagnostic capabilities for gastrointestinal and pancreatic health.
- Shifted from value- and midcap-oriented Russell indices to multiple growth-focused benchmarks, including Russell 2000, 2500, 3000, and Small Cap Comp Growth indices.
Valuation Changes
Summary of Valuation Changes for QuidelOrtho
- The Consensus Analyst Price Target has fallen from $47.14 to $43.57.
- The Future P/E for QuidelOrtho has significantly risen from 11.15x to 152.60x.
- The Net Profit Margin for QuidelOrtho has significantly fallen from 12.99% to 0.92%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.